×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:GMED

Globus Medical Stock Forecast, Price & News

$57.72
+1.58 (+2.81%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$55.86
$57.93
50-Day Range
$53.08
$70.14
52-Week Range
$52.60
$84.23
Volume
469,722 shs
Average Volume
724,298 shs
Market Capitalization
$5.87 billion
P/E Ratio
42.44
Dividend Yield
N/A
Price Target
$83.18

Globus Medical Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
44.1% Upside
$83.18 Price Target
Short Interest
Bearish
6.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.00mentions of Globus Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.65 M Sold Last Quarter
Proj. Earnings Growth
14.29%
From $2.10 to $2.40 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.75 out of 5 stars

Medical Sector

51st out of 1,428 stocks

Surgical & Medical Instruments Industry

8th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Globus Medical logo

About Globus Medical (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock News Headlines

Globus Medical Inc Class A - Stock Quote GMED
What 6 Analyst Ratings Have To Say About Globus Medical
Globus Medical Reports First Quarter 2022 Results
Globus Medical Q1 2022 Earnings Preview
GMED Crosses Below Key Moving Average Level
Why Globus Medical Stock Is Sinking Today
Where Globus Medical Stands With Analysts
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,400
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/02/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$83.18
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+44.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.9
Research Coverage
10 Analysts

Profitability

Net Income
$149.19 million
Pretax Margin
17.90%

Debt

Sales & Book Value

Annual Sales
$958.10 million
Cash Flow
$2.79 per share
Book Value
$17.15 per share

Miscellaneous

Free Float
84,962,000
Market Cap
$5.87 billion
Optionable
Optionable
Beta
1.11














Globus Medical Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Globus Medical stock.
View analyst ratings for Globus Medical
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2022?

10 Wall Street research analysts have issued 12 month price objectives for Globus Medical's shares. Their GMED stock forecasts range from $70.00 to $100.00. On average, they anticipate Globus Medical's share price to reach $83.18 in the next year. This suggests a possible upside of 44.1% from the stock's current price.
View analysts' price targets for Globus Medical
or view top-rated stocks among Wall Street analysts.

How has Globus Medical's stock performed in 2022?

Globus Medical's stock was trading at $72.20 at the beginning of the year. Since then, GMED shares have decreased by 20.1% and is now trading at $57.72.
View the best growth stocks for 2022 here
.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Globus Medical
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings results on Tuesday, May, 10th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by $0.04. The medical device company had revenue of $230.55 million for the quarter, compared to analyst estimates of $232.88 million. Globus Medical had a trailing twelve-month return on equity of 11.95% and a net margin of 14.77%. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 earnings per share.
View Globus Medical's earnings history
.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of $2.10-$2.10 for the period, compared to the consensus estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.03 billion.

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 55, Pay $23.57k)
  • Mr. Daniel T. Scavilla, Pres, CEO & Director (Age 57, Pay $965.17k) (LinkedIn Profile)
  • Mr. Keith W. Pfeil, Sr. VP & CFO (Age 43, Pay $623.41k) (LinkedIn Profile)
  • Ms. Kelly G. Huller Esq., Sr. VP, Gen. Counsel & Sec. (Age 50, Pay $543.02k)
  • Mr. Brian J. Kearns, Sr. VP of Bus. Devel. & Investor Relations (Age 55)
  • Mr. A. Brett Murphy, Exec. VP of International Sales (Age 57)
  • Mr. Steven M. Payne, VP & Controller (Age 51)
  • Mr. Mike Reeder, Exec. Officer
  • Mr. Richard Holifield, Exec. Officer
  • Mr. John Dowling, Exec. Officer

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $57.72.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $5.87 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.36 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,400 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for Globus Medical is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.